{"id":"toremifene-anastrozole","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal bleeding/discharge"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Bone loss/osteoporosis"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1655","moleculeType":"Small molecule","molecularWeight":"405.97"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Toremifene acts as a selective estrogen receptor (ER) antagonist in breast tissue, blocking estrogen-driven proliferation of cancer cells. Anastrozole inhibits the aromatase enzyme, reducing peripheral conversion of androgens to estrogen, thereby lowering circulating estrogen levels. Together, they provide dual suppression of estrogen-dependent breast cancer growth through receptor antagonism and hormone depletion.","oneSentence":"This combination uses toremifene (a selective estrogen receptor modulator) and anastrozole (an aromatase inhibitor) to block estrogen signaling and production in hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:19.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (metastatic or advanced)"}]},"trialDetails":[{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT05472792","phase":"PHASE2","title":"Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-05-17","conditions":"Breast Cancer, Quality of Life","enrollment":90},{"nctId":"NCT04383275","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-23","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT05861271","phase":"PHASE2","title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer Stage I","enrollment":1008},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk","enrollment":700},{"nctId":"NCT04666805","phase":"","title":"Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2020-07-01","conditions":"Breast Cancer","enrollment":1354},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03238703","phase":"PHASE4","title":"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-01","conditions":"HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal","enrollment":""},{"nctId":"NCT03204734","phase":"PHASE2","title":"Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-01-01","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT02089854","phase":"PHASE4","title":"Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-11","conditions":"Female Breast Cancer","enrollment":800},{"nctId":"NCT02097459","phase":"PHASE3","title":"Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-03","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT00437359","phase":"PHASE2","title":"Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"Japan Breast Cancer Research Network","startDate":"2007-05","conditions":"Breast Neoplasms","enrollment":240},{"nctId":"NCT01352091","phase":"PHASE3","title":"Adjuvant AI Combined With Zoladex","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-05","conditions":"Breast Cancer","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Toremifene; Anastrozole","genericName":"Toremifene; Anastrozole","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toremifene is a small molecule used in the treatment of breast cancer, specifically in postmenopausal women with HER2/Neu negative, invasive, or stage 0 breast cancer. Anastrozole is also used in the treatment of breast cancer, particularly in postmenopausal women, and is often compared to tamoxifen and toremifene in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}